NTRA
Natera
October 6, 2026 · intraday
- Rarity
- 1.41
- Peak move
- −6.71%
- Float cap
- $55.4B
Natera is a molecular diagnostics company that sells cell-free DNA testing services across three areas: oncology, women's health, and organ health. Its products include the Signatera test for detecting residual cancer and monitoring recurrence, the Panorama non-invasive prenatal screen and Horizon carrier screening, and Prospera for assessing organ transplant rejection. It sells primarily to physicians, hospitals, and laboratories in the United States, with some prenatal testing in Europe.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
8 events · 0 from SEC or newswire · 0 timed with the move- Key event
reg_fd_disclosureNatera announced new Signatera data at the ASTRO 2026 Annual Meeting, its first participation there, with four oral abstracts including a Memorial Sloan Kettering study in locally advanced rectal cancer showing 100% sensitivity and 97% specificity.
analyst_ratingCitigroup reiterated its Buy rating on Natera on October 6, 2026.
- Key event
product_launchAlliance Foundation Trials launched AFT-70 NAVIGATE, a randomized Phase III MRD-guided breast cancer trial using Natera's Signatera Genome with Genentech's giredestrant in 2,000+ ER-positive/HER2-negative patients at about 200 sites, co-funded by Natera and Genentech.
- Key event
regulatory_approvalJapan's PMDA cleared Natera's Signatera test as a companion diagnostic for muscle-invasive bladder cancer, linking the assay to adjuvant atezolizumab treatment decisions.
insider_saleNatera President of Clinical Diagnostics Solomon Moshkevich sold shares on October 1, 2026 at weighted average prices around $411.62-$415.07 under a Rule 10b5-1 plan, leaving him 106,914 shares.
insider_saleNatera CEO and President Steven Leonard Chapman sold 1,273 common shares on October 1, 2026 at $413.31 per share for about $526,143-$526,544 under a Rule 10b5-1 plan, leaving him 96,926 shares.
institutional_flowInstitutional holders of Natera totaled 940 as of October 2, 2026, holding 150,039,814 shares valued at about $61.57 billion, with net institutional buying of 2,043,116 shares.
analyst_ratingCiti raised its price target on Natera to $480 from $365 while keeping a Buy rating after meeting with management, citing Signatera momentum and a healthy women's and organ health business.